



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,068	05/15/2006	Jens Richard Pedersen	PEDERSEN13	6078
1444	7590	07/07/2009	EXAMINER	
BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW SUITE 300 WASHINGTON, DC 20001-5303			TONGUE, LAKIA J	
ART UNIT	PAPER NUMBER		1645	
MAIL DATE	DELIVERY MODE			
07/07/2009	PAPER			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/541,068	<b>Applicant(s)</b> PEDERSEN ET AL.
	<b>Examiner</b> LAKIA J. TONGUE	<b>Art Unit</b> 1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 12 March 2009.
- 2a) This action is FINAL.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-26,31 and 32 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-26,31 and 32 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO-1668)  
 Paper No(s)/Mail Date \_\_\_\_\_
- 4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date \_\_\_\_\_
- 5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_

**DETAILED ACTION**

1. It is noted that Applicant has again traversed the restriction requirement in the present action. As no additional restriction requirement has been made in the previous office action filed November 13, 2008, it is unclear the purpose for the traversal as the restriction was held final.

Consequently, claims 1, 12-18, 20 and 23 have been amended. Claims 27 and 30 have been canceled. Claims 31 and 33 have been added. Claims 1-26, 31 and 32 are currently pending and under examination.

***Objections Withdrawn***

2. In view of Applicant's amendment, the objection to claim 20 because 'monosachharide' should be spelled 'monosaccharide' is withdrawn.

***Rejections Withdrawn***

3. In view of Applicant's amendment, the rejection of claims 12-15 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention by the use of the phrase "wherein the glycosylated immunoglobulins are intact and/or resistant to proteases such as bacterial proteases and/or pancreatic proteases" and the phrase "immunoglobulins have lost their ability of complement fixation" is withdrawn.

4. In view of Applicant's arguments and amendments, the rejection of claims 12-15 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is withdrawn.

***Rejections Maintained***

***Claim Rejections - 35 USC § 102/103***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

5. The rejection of claims 1-14, 16-26, 31 and 32 under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Stephan et al. (U.S. Patent 4, 734,279) as evidenced by Rudd et al. (Science, 2001; 291: 2370-2376) and Shu et al. (Nahrung, 1998; 42(2): 68-70) as previously applied to claims 1-14 and 16-26 is maintained for the reasons set forth in the previous office action.

Applicant argues that:

1) Stephan et al. do not disclose synthetically glycosylated immunoglobulins directed towards antigens present on the surface of Gram negative bacteria.

2) Combining elements of the invention of Stephan et al. with the disclosures of Shue et al. will not provide the claimed composition.

3) The present invention confers new and improved features to the combined effect of lysozyme and immunoglobulins already known in the art.

Applicant's arguments have been considered and are deemed non-persuasive.

The rejected claims are drawn to an antimicrobial composition comprising lysozyme and synthetically glycosylated immunoglobulins directed towards antigens on the surface of Gram negative bacteria, wherein said synthetically glycosylated immunoglobulins have been produced by dissolving parental immunoglobulins in a solution comprising disaccharide or monosaccharide under conditions resulting in synthetic glycosylation of said parental immunoglobulins, and wherein said antimicrobial composition has increased bactericidal activity at least in part as a result of said synthetic glycosylation.

With regard to Point 1, Stephan et al. disclose an immunoenhancing amount of glycosylated immunoglobulins IgG, IgM and IgA used to protect mice infected with *Pseudomonas aeruginosa*. Absent evidence to the contrary, said glycosylated immunoglobulins are necessarily directed towards antigens present on the surface of Gram negative bacteria.

With regard to Point 2, contrary to Applicant's assertion, the combination of references renders the instant invention obvious. Moreover, it should be remembered that the products of the prior art reference appear to be the same as the product claimed by the applicant because they appear to possess the same or similar functional

Art Unit: 1645

characteristics. The purification or production of a product by a particular process does not impart novelty or unobviousness to a product when the same product is taught by the prior art. This is particularly true when the process does not change properties of the product in an unexpected manner. See *In re Thorpe*, 227 USPTO 964 (CAFC 1985); *In re Marosi*, 218 USPTO 289, 29222-293 (CAFC 1983); *In re Brown*, 173 USPTO 685 (CCPA 1972). Even if applicant's product can be shown to be of higher purity than the product of the prior art reference, applicant needs to show some unexpected and unique utility or property, such as unexpected biologically significant increase in specific activity with which the increased purity, great stability and/or practicality or freedom from some restrictive element or adverse side effects inherent in the product preparations of the prior art or some other secondary consideration which the additional degree of purity imparts to applicants product in order to overcome the aspect of the product's purity.

With regard to Point 3, Applicant's assertion of unexpected results, Applicant has failed to provide evidence supporting said assertion. The MPEP states:

**716.02(b) Burden on Applicant**

**BURDEN ON APPLICANT TO ESTABLISH RESULTS ARE UNEXPECTED AND SIGNIFICANT**

The evidence relied up should establish "that the differences in results are in fact unexpected and unobvious and of both statistical and practical significance." Ex parte Gelles, 22 USPQ2d 1318, 1319 (Bd. Pat. App. & Inter. 1992) (Mere conclusions in appellants' brief that the claimed polymer had an unexpectedly increased impact strength "are not entitled to the weight of conclusions accompanying the evidence, either in the specification or in a declaration."); Ex parte C, 27 USPQ2d 1492 (Bd. Pat. App. & Inter. 1992) (Applicant alleged unexpected results with regard to the claimed soybean plant, however there was no basis for judging the practical significance of data with regard to maturity date, flowering date, flower color, or height of the plant.). See also *In re Nolan*, 553 F.2d 1261, 1267, 193 USPQ 641, 645 (CCPA 1977) and *In re Eli*

Art Unit: 1645

Lilly, 902 F.2d 943, 14 USPQ2d 1741 (Fed. Cir. 1990) as discussed in MPEP § 716.02(c).

#### APPLICANTS HAVE BURDEN OF EXPLAINING PROFFERED DATA

"[A]ppellants have the burden of explaining the data in any declaration they proffer as evidence of non-obviousness." Ex parte Ishizaka, 24 USPQ2d 1621, 1624 (Bd. Pat. App. & Inter. 1992).

#### DIRECT AND INDIRECT COMPARATIVE TESTS ARE PROBATIVE OF NONOBVIOUSNESS

Evidence of unexpected properties may be in the form of a direct or indirect comparison of the claimed invention with the closest prior art which is commensurate in scope with the claims. See In re Boesch, 617 F.2d 272, 205 USPQ 215 (CCPA 1980) and MPEP § 716.02(d) - § 716.02(e). See In re Blondel, 499 F.2d 1311, 1317, 182 USPQ 294, 298 (CCPA 1974) and In re Fouche, 439 F.2d 1237, 1241-42, 169 USPQ 429, 433 (CCPA 1971) for examples of cases where indirect comparative testing was found sufficient to rebut a *prima facie* case of obviousness. The patentability of an intermediate may be established by unexpected properties of an end product "when one of ordinary skill in the art would reasonably ascribe to a claimed intermediate the contributing cause' for such an unexpectedly superior activity or property." In re Magerlein, 602 F.2d 366, 373, 202 USPQ 473, 479 (CCPA 1979). "In order to establish that the claimed intermediate is a contributing cause' of the unexpectedly superior activity or property of an end product, an applicant must identify the cause of the unexpectedly superior activity or property (compared to the prior art) in the end product and establish a nexus for that cause between the intermediate and the end product." Id. at 479.

#### Additionally, 716.01(c) Probative Value of Objective Evidence TO BE OF PROBATIVE VALUE, ANY OBJECTIVE EVIDENCE SHOULD BE SUPPORTED BY ACTUAL PROOF

Objective evidence which must be factually supported by an appropriate affidavit or declaration to be of probative value includes evidence of unexpected results, commercial success, solution of a long-felt need, inoperability of the prior art, invention before the date of the reference, and allegations that the author(s) of the prior art derived the disclosed subject matter from the applicant. See, for example, In re De Blauwe, 736 F.2d 699, 705, 222 USPQ 191, 196 (Fed. Cir. 1984) ("It is well settled that unexpected results must be established by factual evidence." "[A]ppellants have not presented any experimental data showing that prior heat-shrinkable articles split. Due to the absence of tests comparing appellant's heat shrinkable articles with those of the closest prior art, we conclude that appellant's assertions of unexpected results constitute mere argument."). See also In re Lindner, 457 F.2d 506, 508, 173 USPQ 356, 358 (CCPA 1972); Ex parte George, 21 USPQ2d 1058 (Bd. Pat. App. & Inter. 1991).

#### ATTORNEY ARGUMENTS CANNOT TAKE THE PLACE OF EVIDENCE

The arguments of counsel cannot take the place of evidence in the record. In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965). Examples of attorney statements which are not evidence and which must be supported by an appropriate

Art Unit: 1645

affidavit or declaration include statements regarding unexpected results, commercial success, solution of a long-felt need, inoperability of the prior art, invention before the date of the reference, and allegations that the author(s) of the prior art derived the disclosed subject matter from the applicant.

As previously presented, Stephan et al. disclose a composition comprising a lysozyme and an immunoenhancing amount of immunoglobulins IgG, IgM and IgA (see abstract; column 1, lines 10-20). Stephan et al. disclose that mice were infected with *Pseudomonas aeruginosa* and the animals were protected by the administration of the immunoglobulin preparation (see column 2, lines 35-44). Stephan et al. disclose that the composition can be incorporated into a vehicle, such as tablets or ointments. Moreover, Rudd et al. which disclose that in the humoral immune system all of the immunoglobulins and most of the complement components are glycosylated (see abstract).

Stephan et al. do not specifically disclose that the immunoglobulins have affinity to Gram positive bacteria, viruses or antigen determinants on the cell wall of Gram negative bacteria. Moreover, Stephan et al. do not specifically disclose that the lysozyme is conjugated to a monosaccharide.

Shu et al. disclose that polysaccharide chain attachment, which includes monosaccharides such as mannose, to lysozyme is critical for excellent emulsifying properties (see abstract).

It would have been obvious to one of ordinary skill in the art at the time of invention to modify the invention of Stephan et al. with regard to immunoglobulins having affinity to Gram positive bacteria, viruses or antigen determinants on the cell wall of Gram negative bacteria because the substitution of one known element for another

would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Moreover, with regard to lysozyme conjugated to monosaccharide, "it is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." *In re Kerkhoven*, 626 F.2d 846, 850,205 USPQ 1069, 1072 (CCPA 1980).

With regard to claims 1, 16-18 and 22, it should be remembered that the products of the prior art reference appear to be the same as the product claimed by the applicant because they appear to possess the same or similar functional characteristics. The purification or production of a product by a particular process does not impart novelty or unobviousness to a product when the same product is taught by the prior art. This is particularly true when the process does not change properties of the product in an unexpected manner. See *In re Thorpe*, 227 USPTO 964 (CAFC 1985); *In re Marosi*, 218 USPTO 289, 29222-293 (CAFC 1983); *In re Brown*, 173 USPTO 685 (CCPA 1972). Even if applicant's product can be shown to be of higher purity than the product of the prior art reference, applicant needs to show some unexpected and unique utility or property, such as unexpected biologically significant increase in specific activity with which the increased purity, great stability and/or practicality or freedom from some restrictive element or adverse side effects inherent in the product preparations of the prior art or some other secondary consideration which the additional degree of purity imparts to applicants product in order to overcome the aspect of the product's purity.

With regard to claim 2, claim limitations such as "for local use on mucosal membranes and/or skin" are being viewed as limitations of intended use. A recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 458.

With regard to claims 23-26, limitations such as the form of the composition and the range of the lysozyme and glycosylated immunoglobulins are being viewed as limitations of optimizing experimental parameters.

***New Grounds of Rejection Necessitated by Amendment***

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 1, 15-18, 31 and 32 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

Applicant has amended claim 1 to recite "...dissolving parental immunoglobulins....under conditions resulting in synthetic glycosylation of said parental immunoglobulins, and wherein said antimicrobial composition has increased bactericidal activity at least in part as a result of said synthetic glycosylation"; claim 15 to recite "....Activity relative to said parental immunoglobulins"; claims 16-18 and 32 to recite "parental immunoglobulins"; claim 31 to recite "...native naturally glycosylated immunoglobulins, native deglycosylated immunoglobulins, recombinant deglycosylated immunoglobulins and recombinant unglycosylated immunoglobulins". These phrases do not appear in the specification, or original claims as filed. Applicant does not point out specific basis for this limitation in the application, and none is apparent.

To overcome this rejection Applicant must specifically point out the support for this limitation or cancel the new matter from the claims.

### ***Conclusion***

7. No claim is allowed.
  
8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Art Unit: 1645

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAKIA J. TONGUE whose telephone number is (571)272-2921. The examiner can normally be reached on Monday-Friday 8:5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Mondesi can be reached on 571-272-0956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

LJT  
7/5/09

/Robert B Mondesi/  
Supervisory Patent Examiner, Art Unit 1645